Silvia Lopez-Lastra

Silvia Lopez-Lastra

Auto-generated profile, based on publicly available information

Silvia Lopez-Lastra

Owkin

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Cell
Verified
Journal Article
Closed access
ALAi Ing Lim
Ai Ing Lim
YLYan Li
Yan Li
SLSilvia Lopez-Lastra
Silvia Lopez-Lastra
RSRalph Stadhouders
Ralph Stadhouders
FPFranziska Paul
Franziska Paul
JSJames P. Di Santo
James P. Di Santo

1 September 2016 in Immunity
Verified
Journal Article
Closed access
JEJulien Ettersperger
Julien Ettersperger
NMNicolas Montcuquet
Nicolas Montcuquet
GMGeorgia Malamut
Georgia Malamut
NGNicolas Guegan
Nicolas Guegan
SLSilvia Lopez-Lastra
Silvia Lopez-Lastra
BMBertrand Meresse
Bertrand Meresse

1 March 2015 in Cell Reports
Verified
Journal Article
Open access
WXWei Xu
Wei Xu
RDRita G. Domingues
Rita G. Domingues
DFDiogo Fonseca-Pereira
Diogo Fonseca-Pereira
MFManuela Ferreira
Manuela Ferreira
HRHélder Ribeiro
Hélder Ribeiro
HVHenrique Veiga-Fernandes
Henrique Veiga-Fernandes
Innate lymphoid cells (ILCs) are a family of effectors that originate from a common innate lymphoid cell progenitor. However, the transcriptional program that sets the identity of the ILC lineage remains elusive. Here, we show that NFIL3 is a critical regulator of the common helper-like innate lymphoid cell progenitor (CHILP). Cell-intrinsic Nfil3 ablation led to variably impaired development of fetal and adult ILC subsets. Conditional gene targeting demonstrated that NFIL3 exerted its function prior to ILC subset commitment. Accordingly, NFIL3 ablation resulted in loss of ID2(+) CHILP and PLZF(+) ILC progenitors. Nfil3 expression in lymphoid progenitors was under the control of the mesenchyme-derived hematopoietin IL-7, and NFIL3 exerted its function via direct Id2 regulation in the CHILP. Moreover, ectopic Id2 expression in Nfil3-null precursors rescued defective ILC lineage development in vivo. Our data establish NFIL3 as a key regulator of common helper-like ILC progenitors as they emerge during early lymphopoiesis.

1 March 2015
Verified
Journal Article
Closed access
Manuel Vicente Garnacho-CastañoManuel Vicente Garnacho-Castaño
Manuel Vicente Garnacho-Castaño
SLSilvia López-Lastra
Silvia López-Lastra
JMJosé L Maté-Muñoz
José L Maté-Muñoz

5 September 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
Emmanuel ClaveEmmanuel Clave
Emmanuel Clave
IAItauá Leston Araujo
Itauá Leston Araujo
CACécile Alanio
Cécile Alanio
EPEtienne Patin
Etienne Patin
JBJacob Bergstedt
Jacob Bergstedt
TCThe Milieu Intérieur Consortium
The Milieu Intérieur Consortium
The thymus is the primary lymphoid organ where naïve T cells are generated; however, with the exception of age, the parameters that govern its function in healthy humans remain unknown. We characterized the variability of thymic function among 1000 age- and sex-stratified healthy adults of the Milieu Intérieur cohort, using quantification of T cell receptor excision circles (TRECs) in peripheral blood T cells as a surrogate marker of thymopoiesis. Age and sex were the only nonheritable factors identified that affect thymic function. TREC amounts decreased with age and were higher in women compared to men. In addition, a genome-wide association study revealed a common variant (rs2204985) within the T cell receptor TCRA-TCRD locus, between the DD2 and DD3 gene segments, which associated with TREC amounts. Strikingly, transplantation of human hematopoietic stem cells with the rs2204985 GG genotype into immunodeficient mice led to thymopoiesis with higher TRECs, increased thymocyte counts, and a higher TCR repertoire diversity. Our population immunology approach revealed a genetic locus that influences thymopoiesis in healthy adults, with potentially broad implications in precision medicine.

6 February 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
JVJohn P. Veluchamy
John P. Veluchamy
SLSilvia Lopez-Lastra
Silvia Lopez-Lastra
JSJan Spanholtz
Jan Spanholtz
FBFenna Bohme
Fenna Bohme
NKNina Kok
Nina Kok
HVHans van der Vliet
Hans van der Vliet
Therapeutic monoclonal antibodies (mAbs) against the epidermal growth factor receptor (EGFR) act by inhibiting EGFR downstream signaling and by eliciting an NK cell-mediated anti-tumor response. The IgG1 mAb cetuximab has been used for treatment of RASwt metastatic colorectal cancer (mCRC) patients, showing limited efficacy. In the present study we address the potential of adoptive NK cell therapy to overcome these limitations investigating two allogeneic NK cell products, i.e. activated peripheral blood NK cells (A-PBNK) and umbilical cord blood stem cell derived NK cells (UCB-NK). While cetuximab monotherapy was not effective against EGFR- RASwt, EGFR+ RASmut and EGFR+ BRAFmut cells, A-PBNK were able to initiate lysis of EGFR+ colon cancer cells irrespective of RAS or BRAF status. Cytotoxic effects of A-PBNK (but not UCB-NK) were further potentiated significantly by coating EGFR+ colon cancer cells with cetuximab. Of note, a significantly higher cytotoxicity was induced by UCB-NK in EGFR-RASwt (42 ± 8% versus 67 ± 7%), EGFR+ RASmut (20 ± 2% versus 37 ± 6%) and EGFR+ BRAFmut (23 ± 3% versus 43 ± 7%) colon cancer cells compared to A-PBNK and equaled the cytotoxic efficacy of the combination of A-PBNK and cetuximab. The anti-tumor efficacy of UCB-NK cells against cetuximab resistant human EGFR+ RASmut colon cancer cells was further confirmed in an in vivo preclinical mouse model where UCB-NK showed enhanced anti-tumor cytotoxicity against colon cancer independent of EGFR and RAS status. As UCB-NK have been proven safe in a recently conducted phase I clinical trial in acute myeloid leukemia, a fast translation into clinical proof of concept for mCRC could be considered.